CHAPTER 3: DEFINITION OF TERMS

Similar documents
Communicable Disease Control Manual Chapter 4: Tuberculosis

Self-Study Modules on Tuberculosis

Tuberculosis Elimination: The Role of the Infection Preventionist

Core Curriculum on Tuberculosis: What the Clinician Should Know

Fundamentals of Tuberculosis (TB)

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

Tuberculosis Intensive

Tuberculosis Pathogenesis

Mycobacterium tuberculosis. Lecture (14) Dr.Baha, AL-Amiedi Ph. D.Microbiology

TB Intensive San Antonio, Texas December 1-3, 2010

Tuberculosis (TB) Fundamentals for School Nurses

Diagnosis and Medical Management of Latent TB Infection

The Air We Share: Principles and Practices of TB Infection Control

TUBERCULOSIS. Pathogenesis and Transmission

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Contracts Carla Chee, MHS May 8, 2012

Self-Study Modules on Tuberculosis

MYCOBACTERIUM. Mycobacterium Tuberculosis (Mtb) nontuberculous mycobacteria (NTM) Mycobacterium lepray

TB the basics. (Dr) Margaret (DHA) and John (INZ)

Tuberculosis - clinical forms. Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

CDC IMMIGRATION REQUIREMENTS:

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Chapter 4 Diagnosis of Tuberculosis Disease

Transmission and Pathogenesis of Tuberculosis. Transmission and Pathogenesis of Tuberculosis. Mycobacteria. Introduction to the pathogen Transmission

Transmission and Pathogenesis of Tuberculosis

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

Medical Bacteriology- Lecture 10. Mycobacterium. Actinomycetes. Nocardia

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

Tuberculosis. Impact of TB. Infectious Disease Epidemiology BMTRY 713 (A. Selassie, DrPH)

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

has the following disclosures to make:

결핵 전남대학교병원 호흡기내과 권용수

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %

Northwestern Polytechnic University

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Medical Bacteriology- lecture 13. Mycobacterium Actinomycetes

Core Curriculum on Tuberculosis: What the Clinician Should Know DR.RUPNATHJI( DR.RUPAK NATH )

TB Laboratory for Nurses

Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Characteristics of Mycobacterium

Tuberculosis Tools: A Clinical Update

MODULE ONE" TB Basic Science" Treatment Action Group TB/HIV Advocacy Toolkit

Why need to havetb Clearance. To Control and Prevent Tuberculosis

Learning Objectives: Case 1 11/12/2015. Tuberculosis: Focus on Transmission and Pathogenesis. TB: Some Important Terms

TUBERCULOSIS INTRODUCTION. Tuberculosis is an infectious disease that primarily affects the lungs, and it is

TB BASICS: PRIORITIES AND CLASSIFICATIONS

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

What Drug Treatment Centers Can do to Prevent Tuberculosis

#114 - Tuberculosis Update [1]

Latent TB, TB and the Role of the Health Department

Tuberculosis Infection in the US Military

SWABCHA Fact Sheet: Tuberculosis (TB)

Respiratory System الفريق الطبي االكاديمي

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015

TB Infection Control: Fears and Facts Lisa V. Adams, MD Elizabeth A. Talbot, MD Dartmouth Medical School June 2011

Diagnosis and Treatment of Tuberculosis, 2011

Mycobacteria & Tuberculosis PROF.HANAN HABIB & PROF ALI SOMILY DEPRTMENT OF PATHOLOGY, MICROBIOLOGY UNIT COLLEGE OF MEDICINE

Tuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats

Pathology of pulmonary tuberculosis. Dr: Salah Ahmed

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

HISTORY TB = 25% ADULT DEATHS EGYPTIAN MUMMIES: SPINAL TB. 17 th -18th CENTURIES- URBANIZATION MID 24

TB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks

Tuberculosis. WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

HISTORY TB = 25% ADULT DEATHS MID 24 PRE-ANTIBIOTIC ERA

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

At the end of this session, participants will be able to:

Proposed Regs.pdf

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

TB Clinical Guidelines: Revision Highlights March 2014

Contact Investigation

Peggy Leslie-Smith, RN

TB Contact Investigation

Tuberculosis Populations at Risk

New Tuberculosis Guidelines. Jason Stout, MD, MHS

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

"GUARDING AGAINST TUBERCULOSIS IN HEALTHCARE FACILITIES"

The Diagnosis of Active TB. Deborah McMahan, MD TB Intensive September 28, 2017

TB Transmission, Pathogenesis & Infection Control

"GUARDING AGAINST TUBERCULOSIS IN INSTITUTIONAL FACILITIES"

Symptoms Latent TB Active TB

Appendix C. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

TB BASICS: PRIORITIES AND CLASSIFICATIONS

Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)

INDEX CASE INFORMATION

All you need to know about Tuberculosis

Primer on Tuberculosis (TB) in the United States

number Done by Corrected by Doctor Hamid Al Zoubi

TB Intensive San Antonio, Texas November 11 14, 2014

New Standards for an Old Disease:

TUBERCULOSIS CONTACT INVESTIGATION

Transcription:

CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria (bacilli) Microorganisms that retain the colour of the solution they are stained with (during the smear process) even after they have been washed in an acid solution. Most of the acid-fast bacteria (AFB) in patient specimens are mycobacteria, such as (but not only) Mycobacterium tuberculosis. 3.2 Active TB disease Also known as TB disease. People with active TB disease are usually symptomatic and have test results that are consistent with TB disease, such as laboratory tests that are positive for TB bacteria or chest x-ray results that suggest active TB disease. Some forms of active TB disease are infectious. 3.3 Airborne infection isolation room (AIIR) Formerly called a negative pressure isolation room, an AIIR is a room designed to prevent the spread of infectious droplet nuclei, and has engineering controls such as negative-pressure ventilation. 3.4 Airborne precautions A group of controls used to in addition to routine precautions to prevent transmission of organisms such as TB that are transmitted by the airborne route. 3.5 Bacille Calmette-Guerin (BCG) A live, attenuated vaccine given to young children to prevent the most serious forms of TB disease, should they become infected with TB bacteria after receiving the vaccine. People that have received BCG vaccination can have false-positive tuberculin skin test (TST) reactions. History of BCG vaccination does not influence interferon gamma release assay (IGRA) results. 1

3.6 Case A person with suspected or confirmed TB disease. 3.7 Cavities, Cavitary TB disease Hollow spaces in the lungs that can be seen on chest x-rays. Cavities represent areas of lung tissue that have been destroyed by the TB disease process. They are often seen in people with very severe active pulmonary TB disease. Cavities can contain large numbers of TB bacteria, so cases with cavitary TB disease are usually considered highly-contagious. 3.8 Contacts People exposed to someone with infectious TB disease such as family members; roommates or housemates; close friends; coworkers; classmates; and others. 3.9 Contact investigation A systematic process to identify, assess, and when indicated, to provide treatment for active TB disease or latent TB infection to contacts. 3.10 Disseminated TB disease When a person has active TB disease affecting three or more sites at the same time, or where there is evidence of TB bacteria having spread through the blood (hematogenous dissemination). Miliary TB is an example of disseminated TB disease. 3.11 Droplet nuclei Very small droplets of moisture (1 to 5 microns in diameter) that can be expelled when a person coughs, sneezes, speaks, sings or plays a wind instrument. When droplets contain TB bacteria, they are referred to as infectious droplet nuclei. Droplet nuclei can remain suspended in the air for several hours and can travel on air currents to other areas. 3.12 Drug resistant TB disease (DR-TB) Active TB disease caused by TB bacteria that are not killed or inhibited by standard concentrations of one or more TB medications. 2

3.12.1 Multidrug-resistant tuberculosis (MDR-TB) Active TB disease caused by TB bacteria resistant to at least isoniazid and rifampin, with or without resistance to other TB medications. 3.12.2 Extensively drug-resistant tuberculosis (XDR-TB) Active TB disease caused by TB bacteria resistant to at least isoniazid and rifampin and any fluoroquinolone, and at least one of three injectable second-line TB medications (capreomycin, kanamycin and amikacin). 3.13 Drug susceptibility test (DST) Laboratory tests done to identify which TB medications a strain of TB bacteria is susceptible or resistant to. 3.14 Epidemiologic link (epi link) A characteristic TB cases share that might explain where and when TB could have been transmitted between/among them. 3.15 Extrapulmonary TB disease Active TB disease that involves sites other than the lungs, such as the lymph nodes, the pleura, the brain, the kidneys, or the bones. Most kinds of extrapulmonary TB are not infectious. This term is often used interchangeably with non-respiratory TB, but the definitions are slightly different. 3.16 Fit test Testing done to determine which disposable N95 particulate respirator(s) fit a person well enough to prevent inhalation of infectious droplet nuclei (TB bacteria). 3.17 Genotyping Laboratory tests used to determine the genetic pattern of the strain of M. tuberculosis that caused active TB disease in a person. Comparing genotypes from different cases can help identify whether they might be connected (epilinked) to each other and/or other cases. 3

3.18 Infectious When a person is capable of spreading infection. A person with infectious TB disease expels TB bacteria into the air when he or she coughs, sneezes, speaks, sings, or plays a wind instrument. People with laryngeal TB disease (TB laryngitis) can expel TB bacteria when they talk. People with smear-positive, cavitary TB disease or laryngeal TB disease are considered the most infectious. 3.19 Infectious period The time during which a TB case is potentially capable of transmitting TB bacteria. 3.20 Interferon gamma release assay (IGRA) A test used to determine if a person is infected with TB bacteria. The test measures the level of interferon-γ (IFN- γ) released when a sample of a person s blood is exposed to antigens from TB bacteria. IGRAs cannot differentiate between latent TB infection and active TB disease; additional tests (e.g., chest x-ray, testing of specimens for TB bacteria) are needed. 3.21 Latent TB infection (LTBI) People with LTBI have been infected with TB bacteria but have not developed active TB disease. Their TST and IGRA results are usually positive but people with LTBI do not have signs or symptoms of active TB disease or test results that would be consistent with TB disease, such as laboratory tests that are positive for TB bacteria or chest x-ray results that suggest active TB disease. LTBI is not infectious. 3.22 Miliary TB A type of disseminated TB disease that happens when TB bacteria spread through the bloodstream to all part of the body, and then begin to multiply. Miliary TB causes a particular pattern of disease on a chest x-ray that looks like millet seeds scattered throughout the lungs (diffuse micro-nodules). 3.23 Mycobacterial culture Laboratory technique used to identify mycobacteria (such as but not limited to, Mycobacterium tuberculosis) in specimens submitted for TB testing. A positive 4

culture for M. tuberculosis contains TB bacteria. A negative culture contains no detectable TB bacteria. Good quality specimens are important for ensuring reliable culture results. 3.24 Mycobacterium tuberculosis complex M. tuberculosis (including subspecies M. canetti), M. bovis, M. bovis BCG, M. africanum, M. caprae, M. microtic, and M. pinnipedii. All of these species except M. bovis BCG are included in the Canadian case definition of tuberculosis. 3.25 Non-respiratory TB disease Refers to all other sites of TB disease that are not included in the definition of respiratory TB. The definition overlaps with, but is slightly different from the definition of extra-pulmonary TB. 3.26 Nontuberculous mycobacteria (NTM) All mycobacterial species except those that cause TB disease and those that cause leprosy. NTM are also known as atypical mycobacteria or mycobacteria other than TB (MOTT). Common examples include: M. avium complex (MAC), M. kansasii, and M. abscessus. 3.27 Primary Prevention Therapy Treatment for latent TB infection given to contacts whose initial tuberculin skin test (TST) result is less than 5 mm of induration (or whose interferon gamma release assay [IGRA] result is non-reactive) but who are at high risk for developing active TB disease before their 8-week post-exposure TST or IGRA can be done. 3.28 Pulmonary TB disease In Canada, this definition includes: TB disease of the lungs and conducting airways; tuberculous fibrosis of the lung; tuberculous bronchiectasis; tuberculous pneumonia; and tuberculous pneumothorax. 5

3.29 Respiratory TB disease In Canada, pulmonary TB disease includes; tuberculous pleurisy (non-primary); and TB disease of intrathoracic lymph nodes; mediastinum; nasopharynx; nose (septum); and sinus (any nasal). 3.30 Seal check Formerly called fit check ; a procedure performed each time a disposable N95 particulate respirator is put on to check that there is a proper seal between a person s skin and the N95 s/he is wearing. 3.31 Smear Laboratory technique for preparing a specimen so that TB bacteria can be seen with a microscope. 3.32 Source case Person with active TB disease who transmitted TB bacteria to another person or persons. 3.33 Source case investigation Type of contact investigation used to find a source case; usually done when a young child is found to have active TB disease. 3.34 TB meningitis Meningitis caused by TB bacteria. TB meningitis is the most rapidly progressing form of TB disease, with 25% morbidity (permanent neurological deficit) and 15% to 40% mortality despite available treatment. 3.35 Tuberculin A substance made from heat-killed TB bacteria; used to determine whether a person been infected with TB bacteria. Tuberculin is not a vaccine. Repeat injections with tuberculin cannot cause infection with TB bacteria or active TB disease. 6

3.36 Tuberculin skin test (TST) Also known as a tuberculin test or a Mantoux (the name of the testing method). TST is a test used to determine if a person is infected with TB bacteria. TST cannot differentiate between latent TB infection and active TB disease; additional tests (e.g., chest x-ray, testing of specimens for TB bacteria) are needed. 3.37 Tumor necrosis factor-alpha (TNF-alpha) antagonists, inhibitors, or blockers Medications used to treat inflammatory or autoimmune diseases such as rheumatoid arthritis, Crohn s disease, psoriatic arthritis, and juvenile rheumatoid arthritis. 3.38 Window period The time between a contact s last exposure to an infectious TB case and when a tuberculin skin test (TST) or interferon-gamma release assay (IGRA) can reliably detect whether s/he became infected with TB bacteria. 7

SOURCES Adapted from: Menzies D. ed. Canadian Tuberculosis Standards (7 th edition). Canada: Canadian Lung Association, 2014;415-424. Centers for Disease Control and Prevention. Self-Study Modules on Tuberculosis (1 to 5). (2008). Accessed March 31.14 from: http://www.cdc.gov/tb/education/ssmodules/default.htm Centers for Disease Control and Prevention. Self-Study Modules on Tuberculosis (6 to 9). (2014). Accessed March 31.14 from: http://www.cdc.gov/tb/education/ssmodules/default.htm 8